M. Flesch
Impact in
- Oncology top 1%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Hematology top 1%
- Hematopoietic Stem Cell Transplantation
Papers in
- Hematology 27
- Hematopoietic Stem Cell Transplantation 17
- Acute Myeloid Leukemia Research 7
- Hepatology 14
- Hepatocellular Carcinoma Treatment and Prognosis 14
- Co-authors
- Thierry AndréAimery de GramontChristophe LouvetGérard LledoÉlisabeth CarolaLaurent MineurChristophe TournigandArié Figer
In The Last Decade
M. Flesch
72 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 84
- Oncology 1.8k
- Hematology 669
- Hepatology 455
- Pulmonary and Respiratory Medicine 620
- Pathology and Forensic Medicine 339
Countries citing papers authored by M. Flesch
This map shows the geographic impact of M. Flesch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Flesch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Flesch more than expected).
Fields of papers citing papers by M. Flesch
This network shows the impact of papers produced by M. Flesch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Flesch. The network helps show where M. Flesch may publish in the future.
Co-authors
The 25 scholars most cited alongside M. Flesch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 262 | |
| 2 | 2009 | 17 | |
| 3 | 2007 | 68 | |
| 4 | Traitement adjuvant du cancer du côlon : principaux résultats de l’étude MOSAIC* | 2006 | 1 |
| 5 | Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment. | 2006 | 17 |
| 6 | 2006 | 24 | |
| 7 | 2006 | 12 | |
| 8 | 2006 | 38 | |
| 9 | 2006 | 35 | |
| 10 | 2004 | 2 | |
| 11 | 2003 | 185 | |
| 12 | 2002 | 91 | |
| 13 | 2001 | 33 | |
| 14 | 1993 | 15 | |
| 15 | 1992 | 2 | |
| 16 | 1992 | 16 | |
| 17 | 1991 | 12 | |
| 18 | 1988 | 7 | |
| 19 | 1986 | 3 | |
| 20 | Autologous bone marrow transplantation in acute myeloid leukemia in relapse or in complete remission. | 1982 | 20 |
About M. Flesch
M. Flesch is a scholar working on Hematology, Hepatology, Oncology, Genetics and Pathology and Forensic Medicine, having authored 72 papers that have together received 2.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (23 papers), Hematopoietic Stem Cell Transplantation (17 papers), Hepatocellular Carcinoma Treatment and Prognosis (14 papers), Cancer Treatment and Pharmacology (13 papers), Gastric Cancer Management and Outcomes (9 papers), T-cell and B-cell Immunology (8 papers), Acute Myeloid Leukemia Research (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). The work is most often cited by research in Oncology (1.8k citations), Hematology (669 citations), Hepatology (455 citations), Pulmonary and Respiratory Medicine (620 citations) and Pathology and Forensic Medicine (339 citations). M. Flesch has collaborated with scholars based in France, Spain and Belgium. Frequent co-authors include Thierry André, Aimery de Gramont, Christophe Louvet, Gérard Lledo, Élisabeth Carola, Laurent Mineur, Christophe Tournigand, Arié Figer, Marc Buyse and P Hervé. Their work appears in journals such as Journal of Clinical Oncology, Blood, British Journal of Haematology, Annals of Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.